Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

Pictured is an insulin pen manufactured by the Novo Nordisk company on March 14, 2023, in Miami, Florida. The pharmacy benefit managers, the middlemen between manufacturers and insurance companies ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...